168 related articles for article (PubMed ID: 27673283)
1. Consolidation therapy after autologous stem cell transplant in relapsed/refractory Hodgkin lymphoma.
Moskowitz CH
Clin Adv Hematol Oncol; 2016 Sep; 14(9):662-4. PubMed ID: 27673283
[No Abstract] [Full Text] [Related]
2. [Treatment of relapsed Hodgkin lymphoma after autologous stem cell transplantation].
Illés Á; Simon Z; Udvardy M; Magyari F; Jóna Á; Miltényi Z
Orv Hetil; 2017 Aug; 158(34):1338-1345. PubMed ID: 28823212
[TBL] [Abstract][Full Text] [Related]
3. Post Transplant Outcome of a Multicenter Phase II Study of Brentuximab Vedotin as First Line Salvage Therapy in Relapsed/Refractory HL Prior to AHCT.
Clin Adv Hematol Oncol; 2016 Feb; 14(2 Suppl 1):7-8. PubMed ID: 27007003
[No Abstract] [Full Text] [Related]
4. Strategies for Management of Relapsed or Refractory Hodgkin Lymphoma.
Gordon LI
J Natl Compr Canc Netw; 2017 May; 15(5S):716-718. PubMed ID: 28515253
[TBL] [Abstract][Full Text] [Related]
5. [Fundamental approaches to the treatment of refractory and relapsed Hodgkin lymphoma].
Filatova LV; Tarasenkova AA; Semiglazova TIu; Gershanovich ML
Vopr Onkol; 2012; 58(4):443-53. PubMed ID: 23607197
[No Abstract] [Full Text] [Related]
6. Quality of life results from a phase 3 study of brentuximab vedotin consolidation following autologous haematopoietic stem cell transplant for persons with Hodgkin lymphoma.
Ramsey SD; Nademanee A; Masszi T; Holowiecki J; Abidi M; Chen A; Stiff P; Viviani S; Sweetenham JW; Radford J; Zhu Y; Bonthapally V; Thomas E; Richhariya A; Hunder NN; Walewski J; Moskowitz CH
Br J Haematol; 2016 Dec; 175(5):860-867. PubMed ID: 27649689
[TBL] [Abstract][Full Text] [Related]
7. Brentuximab vedotin plus bendamustine versus platinum-based regimens as 1st salvage therapy and 'bridge' to autologous hematopoietic stem cell transplantation for relapsed/refractory Hodgkin lymphoma.
Kaloyannidis P; Al Zayer M; Al Darweesh M; Al Batran M; Al Garni A; Al Naim A; Al Hashmi H; Kanfar S
Leuk Lymphoma; 2023 Mar; 64(3):742-745. PubMed ID: 36628991
[No Abstract] [Full Text] [Related]
8. Current salvage therapies in Hodgkin lymphoma.
Chohan K; Ansell SM
Leuk Lymphoma; 2022 Jun; 63(6):1267-1280. PubMed ID: 35037568
[TBL] [Abstract][Full Text] [Related]
9. [Novel treatment options in relapsed and refracter Hodgkin lymphomas].
Illés Á; Jóna Á; Simon Z; Udvardy M; Miltényi Z
Orv Hetil; 2015 Nov; 156(45):1824-33. PubMed ID: 26522856
[TBL] [Abstract][Full Text] [Related]
10. Updated Efficacy and Safety Data From the AETHERA Trial of Consolidation With Brentuximab Vedotin After Autologous Stem Cell Transplant (ASCT) in Hodgkin Lymphoma Patients at High Risk of Relapse.
Clin Adv Hematol Oncol; 2016 Feb; 14(2 Suppl 1):17-8. PubMed ID: 27007008
[No Abstract] [Full Text] [Related]
11. The role of transplantation in Hodgkin lymphoma.
Broccoli A; Zinzani PL
Br J Haematol; 2019 Jan; 184(1):93-104. PubMed ID: 30407612
[TBL] [Abstract][Full Text] [Related]
12. Autologous and allogeneic stem cell transplantation in Hodgkin's lymphoma.
Sureda A
Hematol Oncol Clin North Am; 2007 Oct; 21(5):943-60. PubMed ID: 17908630
[TBL] [Abstract][Full Text] [Related]
13. Brentuximab vedotin containing salvage followed by consolidation post autologous hematopoietic stem cell transplantation in high risk relapsed refractory classical Hodgkin lymphoma.
Damlaj M; Abuelgasim KA; Alhejazi A; Alahmari B; Alaskar A; Alzahrani M
Bone Marrow Transplant; 2020 Dec; 55(12):2322-2325. PubMed ID: 32404976
[No Abstract] [Full Text] [Related]
14. Tumor associated macrophages in relapsed and refractory Hodgkin lymphoma.
Casulo C; Arcila M; Bohn OL; Teruya-Feldstein J; Maragulia J; Moskowitz CH
Leuk Res; 2013 Sep; 37(9):1178-83. PubMed ID: 23706570
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness analysis of consolidation with brentuximab vedotin for high-risk Hodgkin lymphoma after autologous stem cell transplantation.
Hui L; von Keudell G; Wang R; Zeidan AM; Gore SD; Ma X; Davidoff AJ; Huntington SF
Cancer; 2017 Oct; 123(19):3763-3771. PubMed ID: 28640385
[TBL] [Abstract][Full Text] [Related]
16. Relapsed Hodgkin lymphoma: management strategies.
Montanari F; Diefenbach C
Curr Hematol Malig Rep; 2014 Sep; 9(3):284-93. PubMed ID: 24942298
[TBL] [Abstract][Full Text] [Related]
17. Management of relapsed and refractory classical Hodgkin lymphoma in children and adolescents.
Daw S; Wynn R; Wallace H
Br J Haematol; 2011 Feb; 152(3):249-60. PubMed ID: 21133886
[TBL] [Abstract][Full Text] [Related]
18. Marrow-ablative treatment and autologous stem cell transplantation in follicular NHL.
Bachy E; Salles G
Best Pract Res Clin Haematol; 2011 Jun; 24(2):257-70. PubMed ID: 21658622
[TBL] [Abstract][Full Text] [Related]
19. Relapsed/refractory Hodgkin lymphoma: what is the best salvage therapy and do we need RIC-alloSCT?
Hertzberg M
Hematol Oncol Clin North Am; 2014 Feb; 28(1):123-47. PubMed ID: 24287072
[TBL] [Abstract][Full Text] [Related]
20. Five-Year Survival Data Demonstrating Durable Responses From a Pivotal Phase 2 Study of Brentuximab Vedotin in Patients With Relapsed or Refractory Hodgkin Lymphoma.
Clin Adv Hematol Oncol; 2016 Feb; 14(2 Suppl 1):6. PubMed ID: 27007002
[No Abstract] [Full Text] [Related]
[Next] [New Search]
